CAPR

Capricor Therapeutics Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$486.04M
P/E Ratio
—
EPS
$-2.45
Beta
0.72
52W High
$40.37
52W Low
$2.96
50-Day MA
$9.01
200-Day MA
$23.25
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
78.74
PEG Ratio
0.38

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$11.13M
Gross Profit (TTM)$-99.73M
EBITDA$-133.07M
Operating Margin0.00%
Return on Equity-73.70%
Return on Assets-33.60%
Revenue/Share (TTM)$0.24
Book Value$4.24
Price-to-Book2.21
Price-to-Sales (TTM)25.15
EV/Revenue18.12
EV/EBITDA-2.73
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-7.90%
Shares Outstanding$58.14M
Float$42.60M
% Insiders9.44%
% Institutions76.46%

Historical Volatility

HV 10-Day
53.14%
HV 20-Day
70.44%
HV 30-Day
69.05%
HV 60-Day
67.40%
HV Rank
—

Volatility is currently contracting

Analyst Ratings

Consensus ($27.00 target)
2
Buy
7
Hold

Latest News

Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (CAPR) Investors to Their Right to Seek Lead Plaintiff Status Before September 29, 2026

New York, New York--(Newsfile Corp. - September 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.

Newsfile Corp9/25/2026Neutral
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action.

PRNewsWire9/25/2026Neutral
Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Seek a Leadership Role Before September 28, 2026

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).

GlobeNewsWire9/25/2026Neutral
CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets 64% after Clinical Data Issues Revealed – BFA Law Notifies Investors of the Imminent September 28 Deadline

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

GlobeNewsWire9/25/2026Neutral
CAPR FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR

New York, New York--(Newsfile Corp. - September 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp9/24/2026Neutral
Kaplan Fox & Kilsheimer LLP Announces the Filing of a Securities Class Action Against Capricor Therapeutics, Inc. (CAPR) - Deadline is September 29, 2026

New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.

Newsfile Corp9/24/2026Neutral
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline

SAN FRANCISCO, Sept. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action.

PRNewsWire9/24/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CAPR and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/26/2026